BrightSpring Health Services (BTSG)
Combines specialty and community pharmacy with home-based clinical and personal care.
Something off on this page? Send us feedback.
Dispenses specialty, infusion, and long-term-care medications while delivering home health, hospice, primary, rehabilitation, and personal care across the United States and Canada. Pharmacy generates most revenue, with reimbursement led by Medicare, Medicaid, commercial insurers, and pharmacy benefit managers.
Dispenses infused, specialty, and long-term-care medications through Pharmacy Solutions, spanning Infusion and Specialty Pharmacy and Home and Community Pharmacy. Its local network combines dispensing, delivery, medication management, and clinical support for medically complex patients across the United States and Canada.
Provider Services delivers Home Health Care, including hospice and home-based primary care, alongside Rehab Care and Personal Care. Shared clinical teams and medication-management programs coordinate pharmacy and care in home and community settings. ResCare Community Living is no longer part of the portfolio.
Pharmacy generates most revenue, while Medicare, Medicaid, commercial insurers, pharmacy benefit managers, and care-facility customers fund the business. Reimbursement rules, drug purchasing economics, referrals, and access to pharmacists, nurses, therapists, and caregivers shape operations.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 3, 2026 | Deutsche Bank | Reiterate | Rating: —Target: $60 | Target: $70 |
| Jul 14, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $71 | Target: $80 |
| Jul 14, 2026 | KeyBanc | Reiterate | Rating: —Target: $60 | Target: $80 |
| Jul 13, 2026 | Wells Fargo | Reiterate | Rating: —Target: $61 | Target: $78 |
| Jul 13, 2026 | Guggenheim | Initiate | Rating: —Target: — | Target: $81 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $550.4M · Total debt $2.39B · Total assets $5.99B · Shareholders' equity $2.05B
- Revenue
- $3.87B
- Operating income
- $144.6M
- Net income
- $86.7M
No dividends on record.
| Institutions | ≈ 103.77% | 205.32M shares | |
|---|---|---|---|
| 434 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.47% | 934.2K shares | |
| 11 holders · as of Sep 16, 2026 | |||
| Adds to | 104.24% | ||
197.86M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 104.24%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Kohlberg Kravis Roberts & Co. L.P.Institution | 13.56% | 26.83M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 12.14% | 24.03M | as of Jun 30, 2026 |
FMR LLCInstitution | 6.77% | 13.39M | as of Jun 30, 2026 |
Invesco Ltd.Institution | 6.04% | 11.94M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.03% | 9.95M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | Scott A. Greenwell | officer: President, PharMerica | −15,099 | $57.91 |
| Jun 5, 2026 | Jennifer A. Phipps | officer: Chief Financial Officer | −35,000 | $58.75 |
| Jun 5, 2026 | Lisa A. Nalley | officer: See Remarks | −35,000 | $58.75 |
| Jun 5, 2026 | Jon B. Rousseau | director, officer: See Remarks | −260,000 | $58.75 |
| Jun 5, 2026 | Phoenix Aggregator L.P. KKR | 10 percent owner | −14,669,771 | $58.45 |
- CVS Health
Omnicare division is the #1 LTC/institutional pharmacy rival to PharMerica.
- Option Care Health
Nation's largest independent home infusion rival to BrightSpring's Amerita unit.
- The Pennant Group
Home-health & hospice co-acquirer of Amedisys/LHC branches in shared markets.
- Addus HomeCare
Personal care, hospice, and home health peer named in BrightSpring's 10-K.
- Chemed
VITAS subsidiary — largest US hospice provider, vs BrightSpring's hospice line.
- Aveanna Healthcare
Home health, hospice, and private-duty peer named in BrightSpring's 10-K.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BrightSpring Health Services | $56.55 | +1.24% | $10.96B | 41.7 | 27.7 | 0.8 | +23.0% |
| CVS Health | $87.49 | −0.13% | $111.77B | 23.2 | 10.8 | 0.3 | +7.3% |
| Option Care Health | $24.29 | +1.42% | $3.59B | 18.0 | 12.4 | 0.6 | +1.9% |
| The Pennant Group | $39.84 | +2.26% | $1.35B | 43.3 | 27.4 | 1.2 | +35.8% |
| Addus HomeCare | $116.57 | +1.05% | $2.15B | 20.2 | 16.2 | 1.5 | +8.0% |
| Chemed | $499.75 | +0.03% | $6.53B | 25.1 | 19.4 | 2.5 | +8.8% |
| Aveanna Healthcare | $13.28 | −1.16% | $2.93B | 10.6 | 15.5 | 1.1 | +13.7% |
| Median | 21.7 | 15.9 | 1.2 | +8.4% |